Figure 2.

Disposition of patients taking and not taking RAAS inhibitors. ^aExcluded from the efficacy analysis: 1 patient who did not receive patiromer and 1 patient with a protocol violation and no postbaseline serum potassium observations. Excluded from the safety analysis: 1 patient who did not receive patiromer. HK indicates hyperkalemia; RAASi, renin–angiotensin–aldosterone system inhibitor.